Emily Pei-Ying Lin

Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy

Satya Das, Kristen K. Ciombor, Sigurdís Haraldsdóttir et al. · The Oncologist · 2020 · 42 citations · Full text

Irae Onset, Cancer Management, Immunology +24

Immune checkpoint inhibitors (ICIs) in gastrointestinal (GI) cancer: Immune-related adverse events (IRAEs) and efficacy.

Satya Das, Kristen K. Ciombor, Sigurdís Haraldsdóttir et al. · Journal of Clinical Oncology · 2019 · 15 citations

Gi Cancer Pts, Cancer Management, Immunology +19

Priming PD-L1 expression by chemotherapeutic agents in non-small cell lung cancers.

Emily Pei-Ying Lin, Ching‐Yao Yang, Ching‐Wen Lin et al. · Journal of Clinical Oncology · 2017 · 12 citations

Immunology, Immunotherapeutics, Immunotherapy +17

AptBCis1, An Aptamer–Cisplatin Conjugate, Is Effective in Lung Cancer Leptomeningeal Carcinomatosis

Bo‐Tsang Huang, Wei‐Yun Lai, Chen-Lin Yeh et al. · ACS Nano · 2024 · 10 citations · Full text